Dengue Pt 2 - ENTO 210

Dengue Virus Overview

Disease Cycle

  • Transmission: The dengue virus is primarily transmitted through female Aedes mosquitoes, which include Aedes aegypti and Aedes albopictus. These mosquitoes acquire the virus when they feed on the blood of an infected human.

  • Acquisition Process: After a mosquito feeds on infected blood, the virus replicates inside the mosquito.

Incubation

  • Time Frame: The extrinsic incubation period of the dengue virus is approximately 10 days, during which the virus develops within the mosquito's intestinal tract and migrates to its salivary glands.

Infectious Lifespan

  • Mosquito Lifespan: Adult Aedes mosquitoes remain infectious for their lifespan of approximately 30 days. This prolonged lifespan increases the chances of transmission to humans.

Transmission Efficiency

  • Infectious Dose: It is noteworthy that as few as 100 viral particles are sufficient to establish an infection, underscoring the efficiency of the virus coupled with the mosquito's lifespan and its ability to replicate the virus efficiently.

Transovarial Transmission

  • Gender Differences: The dengue virus is not typically found in male mosquitoes, as they do not engage in blood feeding; rather, they primarily feed on nectar.

  • Transovarial Passage: Female mosquitoes can transmit the virus to their eggs, resulting in the birth of infected offspring, contributing to the endemic nature of the disease.

  • Transstadial Transmission: Pathogens like the dengue virus can also move between developmental stages in the mosquito, although this is primarily discussed in relation to other vectors like ticks.

Infection Dynamics

  • Human Transmission: Human-to-human transmission of dengue predominantly occurs through mosquito vectors. Initial infections in humans can often be mild and asymptomatic.

  • Severe Secondary Infections: A notable aspect of dengue is that a second infection with a different serotype can lead to severe clinical manifestations due to the phenomenon of antibody-dependent enhancement.

Phases of Infection

  1. Febrile Phase: Characterized by a sudden onset of fever and mild symptoms such as headache and muscle pain.

  2. Critical Phase: This phase may occur after the febrile phase, where severe complications such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) can develop.

  3. Recovery Phase: During this phase, patients may experience prolonged recovery times alongside lingering symptoms.

Sylvatic Cycle and Emergence

  • Sylvatic Cycle: The sylvatic cycle refers to the transmission of the dengue virus among wild animal populations, primarily non-human primates like monkeys, allowing the virus to persist in nature.

  • Origins: Dengue virus likely originated within these sylvatic cycles before spilling over into human populations, particularly in areas where human activities intersect with wildlife habitats, facilitating zoonotic transmission.

  • Public Health Importance: Understanding the sylvatic cycle is critical for predicting and controlling outbreaks, especially with the emergence of new serotypes such as dengue 5.

Clinical Manifestations of Dengue

  • Symptom Variability: Approximately 50% of infected individuals may remain asymptomatic, complicating diagnosis and management.

  • Initial Symptoms: The most common initial symptom is undifferentiated fever, presenting as general malaise without specific identifiable symptoms.

Classic Dengue Fever

  • Symptoms: This is marked by high fever, severe muscle and joint pain (often referred to as "break bone fever"), nausea, rash, and prolonged recovery time.

Severe Disease Manifestations

  • Dengue Hemorrhagic Fever (DHF): Presents with bleeding tendencies (e.g., nosebleeds, gum bleeding) and can lead to dangerously low blood pressure, known as dengue shock syndrome.

  • Dengue Shock Syndrome (DSS): Characterized by severe circulatory collapse, where timely medical intervention is critical to prevent mortality.

WHO Criteria for DHF

To diagnose DHF, the World Health Organization (WHO) criteria include:

  • Presence of fever and hemorrhagic tendency.

  • Thrombocytopenia (low platelet count).

  • Evidence of plasma leakage as identified through clinical indicators.

  • A positive tourniquet test indicative of bleeding tendencies.

Risks Associated with Secondary Infections

  • Antibody-Dependent Enhancement (ADE): Subsequent infections pose significant risks of increased disease severity. Pre-existing antibodies from the first infection may bind to the new serotype's virus but fail to neutralize it, resulting in enhanced replication and worse outcomes.

  • Macrophage Hijacking: Infected macrophages facilitate higher viral loads, further exacerbating disease severity and potential complications.

  • Increased Risk of DHF: The risk of severe disease manifestation, particularly DHF, is significantly heightened (up to 100 times) after secondary infections with different serotypes, necessitating public health awareness and preventive strategies.

Conclusion

Understanding the complex dynamics of dengue transmission, clinical manifestations, and the implications of antibody-dependent enhancement is essential for developing effective public health strategies and improving patient care. For further insights into the phenomenon of ADE, supplementary resources and educational videos are recommended.